Two cells has developed a method to harvest mesenchymal stem cells (MSC) from healthy human synovial cells and injects them after expansion into the damaged knee. A clinical trial will be started in 2017 and products launched in 2020. First products will address cartilage damage caused by sports or accident, and later expansion to osteoarthritis is planed. Chugai will market this service in Japan.
Two Cells press release, April 25, 2016
Chugai concludes license agreement with Two Cells Inc. on knee cartilage cell theerapy